Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial
Year: 2015
Type: article
Abstract: The binding of CXCR4 with its ligand (stromal derived factor-1 [SDF-1]) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. This effect of CXCR4/SDF-1 interaction may be undesirable during the early phase of hematopoietic stem cell transplantation (HSCT). We hypothesized that blocking CXCR4/SDF-1 interaction after HSCT promotes hematopoiesis by inducing HSPC proliferation. We have found that giving AMD3100 (plerixafor) after HSCT enhanced recovery of all donor cell lineages in murine transplant models (Kang, PLOS ONE 2010).
Authors: Michael M.B. Green, Mitchell E. Horwitz, Yubin Kang, Nelson J. Chao, Gwynn D. Long, David Rizzieri, Cristina Gasparetto, Anthony D. Sung, Stefanie Sarantopoulos, Zhiguo Li, Kelly Corbet, Emily Riggan-Stuelke, Keith Sullivan, Beth Wilson, Saurabh Chhabra, Luciano V. Costa, Alice Mims, Robert Stuart
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2128874744